RespiratoryNCT06670560
Onco-Respirology Epidemiology Based on Real-world Big Data in Respiratory Medicine
An observational study of Respiratory and Epidemiology, run by Zhou Chengzhi at 1 site in China.
Trial summary
The purpose of this observational study is to understand the changes in the types of respiratory patients hospitalized in China in recent years through a multicenter retrospective clinical study, and at the same time to understand the reasons for hospitalization and the distribution of different tumor types in… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Respiratory, Epidemiology, Neoplasms
- How many people
- 100,000 participants
- Where
- 1 siteChina
- Study dates
- 5 Sep 2024to Jun 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: A respiratory oncology epidemiology study based on real-world big data from respiratory medicine, with retrospective data collected from respiratory medicine inpatients at a multicenter for nearly 10 years.
Who may be able to join
- Clinical diagnosis of Respiratory diseases Must be an inpatient
Who cannot join
- Non-respiratory inpatients
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this observational study is to understand the changes in the types of respiratory patients hospitalized in China in recent years through a multicenter retrospective clinical study, and at the same time to understand the reasons for hospitalization and the distribution of different tumor types in oncology patients, so as to provide data support and theoretical basis for the future development of China's respiratory department.
The main questions it aims to answer are
- the trend of change of respiratory diseases in China in the past 10 years.
- the trend of change in the causes of hospitalization of respiratory tumor patients in China in the past 10 years.
- the trend of the proportion of each tumor in the respiratory department in China over the past 10 years.
- Conditions
- Respiratory, Epidemiology, Neoplasms
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
proportion
- to explore the trend of respiratory diseases (COPD, asthma, bronchiectasis, lung infection, lung cancer, etc.) over the past 10 years in China.
- to explore the trend of the causes of hospitalization of respiratory tumor patients (pulmonary embolism, airway stenosis, post-surgical complications, lung infection, pneumothorax, tuberculosis, etc.) in China over the past 10 years.
- to explore the trend of the proportion of each tumor in the respiratory department (brain tumor, nasopharyngeal cancer, thyroid cancer, lung cancer, breast cancer, liver cancer, etc.) over the past 10 years in China.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Nov 2024
- Study start5 Sep 2024
- Primary completionApr 2026 (estimated)
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for RespiratoryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 100,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhou Chengzhi
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Zhou Chengzhi, Guangzhou Institute of Respiratory Disease
- Investigators
- Xiaohong Xie, Study chair, The First Affiliated Hospital of Guangzhou Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06670560
- Sponsor's protocol ID
- CROC-24-10
- Status last verified
- Nov 2024
- First submitted
- 31 Oct 2024
- Last updated
- 7 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Onco-Respirology Epidemiology Based on Real-world Big Data in Respiratory Medicine
- ClinicalTrials.gov ID
- NCT06670560
- Acronym / sponsor ID
- CROC-24-10
- Conditions
- Respiratory, Epidemiology, Neoplasms
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 100,000 participants (estimated)
- Lead sponsor
- Zhou ChengzhiUniversity, hospital or other
- Study start
- 5 Sep 2024 (actual)
- Primary completion
- Apr 2026 (estimated)
- Study completion
- Jun 2026 (estimated)
- First posted
- 1 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this observational study is to understand the changes in the types of respiratory patients hospitalized in China in recent years through a multicenter retrospective clinical study, and at the same time to understand the reasons for hospitalization and the distribution of different tumor types in oncology patients, so as to provide data support and theoretical basis for the future development of China's respiratory department.
The main questions it aims to answer are
- the trend of change of respiratory diseases in China in the past 10 years.
- the trend of change in the causes of hospitalization of respiratory tumor patients in China in the past 10 years.
- the trend of the proportion of each tumor in the respiratory department in China over the past 10 years.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- A respiratory oncology epidemiology study based on real-world big data from respiratory medicine, with retrospective data collected from respiratory medicine inpatients at a multicenter for nearly 10 years.
Key inclusion criteria (1 listed)
- Clinical diagnosis of Respiratory diseases Must be an inpatient
Key exclusion criteria (1 listed)
- Non-respiratory inpatients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
proportion
Time frame: 10 years
1. to explore the trend of respiratory diseases (COPD, asthma, bronchiectasis, lung infection, lung cancer, etc.) over the past 10 years in China. 2. to explore the trend of the causes of hospitalization of respiratory tumor patients (pulmonary embolism, airway stenosis, post-surgical complications, lung infection, pneumothorax, tuberculosis, etc.) in China over the past 10 years. 3. to explore the trend of the proportion of each tumor in the respiratory department (brain tumor, nasopharyngeal cancer, thyroid cancer, lung cancer, breast cancer, liver cancer, etc.) over the past 10 years in China.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Nov 2024.
Related trials for Respiratory
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xiaohong Xie study chair
The First Affiliated Hospital of Guangzhou Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Respiratory and Epidemiology, run by Zhou Chengzhi at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
proportion (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2024.